Grant Pickering - Nov 7, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact
Stock symbol
PCVX
Transactions as of
Nov 7, 2024
Transactions value $
-$131,488
Form type
4
Date filed
11/8/2024, 08:46 PM
Previous filing
Nov 4, 2024
Next filing
Nov 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Sale -$23.3K -227 -0.16% $102.68 138K Nov 7, 2024 By Children's Trust F1, F2, F3
transaction PCVX Common Stock Sale -$47.9K -463 -0.33% $103.43 138K Nov 7, 2024 By Children's Trust F1, F3, F4
transaction PCVX Common Stock Sale -$39.5K -377 -0.27% $104.71 138K Nov 7, 2024 By Children's Trust F1, F3, F5
transaction PCVX Common Stock Sale -$12.2K -116 -0.08% $105.50 137K Nov 7, 2024 By Children's Trust F1, F3
transaction PCVX Common Stock Sale -$28.8K -281 -0.2% $102.64 138K Nov 7, 2024 By Children's Trust F1, F6, F7
transaction PCVX Common Stock Sale -$37.5K -363 -0.26% $103.36 138K Nov 7, 2024 By Children's Trust F1, F4, F7
transaction PCVX Common Stock Sale -$45.4K -434 -0.31% $104.72 138K Nov 7, 2024 By Children's Trust F1, F5, F7
transaction PCVX Common Stock Sale -$11.1K -105 -0.08% $105.50 137K Nov 7, 2024 By Children's Trust F1, F7
transaction PCVX Common Stock Options Exercise $26.50 +663 +0.15% $0.04 436K Nov 7, 2024 Direct
transaction PCVX Common Stock Options Exercise $28.7K +14.1K +3.24% $2.03 450K Nov 7, 2024 Direct
transaction PCVX Common Stock Options Exercise $85.6K +16K +3.56% $5.35 466K Nov 7, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -663 -100% $0.00 0 Nov 7, 2024 Common Stock 663 $0.04 Direct F8
transaction PCVX Stock Option (right to buy) Options Exercise $0 -14.1K -8.44% $0.00 153K Nov 7, 2024 Common Stock 14.1K $2.03 Direct F8
transaction PCVX Stock Option (right to buy) Options Exercise $0 -16K -7.32% $0.00 203K Nov 7, 2024 Common Stock 16K $5.35 Direct F8
transaction PCVX Performance Stock Option (right to buy) Award $0 +198K $0.00 198K Nov 7, 2024 Common Stock 198K $102.70 Direct F9
transaction PCVX Performance Restricted Stock Units Award $0 +80.6K $0.00 80.6K Nov 7, 2024 Common Stock 80.6K $0.00 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $102.19 to $103.06. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $103.28 to $104.08. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 The price reported is a weighted-average price. The shares were sold at prices ranging from $104.405 to $105.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 The price reported is a weighted-average price. The shares were sold at prices ranging from $102.09 to $103.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7 Shares are held directly by a trust for the benefit of the Reporting Person's son.
F8 Stock Option is fully vested and exercisable.
F9 As part of a company-wide grant to all eligible employees of the Issuer, on November 7, 2024 (the "Grant Date"), the Reporting Person was granted a performance stock option to purchase 197,784 shares of the Issuer's Common Stock at a per share exercise price of $102.70. The option is subject to (1) a service-based vesting condition (vesting as to one-third of the shares on each of the third, fourth and fifth anniversaries of the Grant Date) and (2) a performance-vesting condition (which generally requires that the trading price of the Issuer's Common Stock average, over a one-year period, is at least $154.05 (150% of the Grant Date closing price)).
F10 Represents the target number of shares of Issuer's Common Stock underlying an award of performance restricted stock units ("PSUs"). Each PSU represents the contingent right to receive one share of the Issuer's Common Stock. The attainment of the performance vesting condition will be based on the Issuer's percentile rank within a peer group based on total shareholder return ("TSR") during a four-year performance period that commenced on November 7, 2024, the Grant Date, subject to the Reporting Person's continuous service with the Issuer through completion of the performance period. The actual number of shares of the Issuer's Common Stock deliverable with respect to the award varies based on performance and ranges from 0% to 250% of the target number of shares.